Encision Reports Fourth Quarter and Fiscal Year 2009 Results

BOULDER, Colo., May 19 /PRNewswire-FirstCall/ -- Encision Inc. (OTC Bulletin
Board: ECIA), a medical device company owning patented surgical technology
that is emerging as a standard of care in minimally-invasive surgery, reported
its financial results for its fourth quarter and fiscal year ended March 31,
2009.

Net sales for the fourth quarter of fiscal year 2009, ended March 31, 2009,
totaled $3.1 million, representing a 3% decrease over net sales of $3.2
million for the prior fiscal year's fourth quarter. The Company recorded net
income of $16 thousand or $.00 per share for the fourth quarter of fiscal year
2009 compared to net income of $49 thousand or $.01 per share for the fourth
quarter of fiscal year 2008. Gross profit margin for the fourth quarter of
fiscal year 2009 was 64% as compared to 63.5% for the fourth quarter of fiscal
year 2008.

Net sales for the fiscal year ended March 31, 2009 totaled $12.8 million,
representing a 6% increase over net sales of $12.1 million for the prior
fiscal year. The Company recorded net income of $160 thousand or $.02 per
share for the fiscal year 2009 compared to a net loss of $179 thousand or $.03
per share for the fiscal year 2008. Gross profit margin for the fiscal year
2009 was 62.3% as compared to 63% for the fiscal year 2008.

"Overall, our fiscal year 2009 was satisfactory given the challenges that the
medical device industry has faced during the most recent quarters. This fiscal
year was our first profitable fiscal year since fiscal year 2004," said Jack
Serino, President and CEO of Encision Inc. "We look forward to the coming
fiscal year, especially after entering a sales representation agreement with
Caldera Medical and signing a non-exclusive manufacturing, supply and
licensing agreement with Intuitive Surgical."

Encision Inc. designs, develops, manufactures and markets innovative surgical
devices that allow surgeons to optimize technique and patient safety during a
broad range of surgical procedures. Based in Boulder, Colorado, the Company
pioneered the development of patented AEM(R) Laparoscopic Instruments to
improve electrosurgery and reduce the chance for patient injury in minimally
invasive surgery.

In accordance with the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995, the Company notes that statements in this press
release and elsewhere that look forward in time, which include everything
other than historical information, involve risks and uncertainties that may
cause actual results to differ materially from those indicated by the
forward-looking statements. Factors that could cause the Company's actual
results to differ materially include, among others, its ability to increase
net sales through the Company's distribution channels, insufficient quantity
of new account conversions, insufficient cash to fund operations, scale up
production to meet delivery obligations, delay in developing new products and
receiving FDA approval for such new products and other factors discussed in
the Company's filings with the Securities and Exchange Commission. Readers are
encouraged to review the risk factors and other disclosures appearing in our
filings with the Securities and Exchange Commission. We do not undertake any
obligation to update publicly any forward-looking statements, whether as a
result of the receipt of new information, future events, or otherwise.

CONTACT: Marcia McHaffie, Encision Inc., 303-444-2600, mmchaffie@encision.com

Encision Inc.
Condensed Balance Sheets
(Amounts in thousands)
(Audited)

March 31, March 31,
2009 2008
ASSETS
Cash and cash equivalents $85 $71
Accounts receivable, net 1,264 1,453
Inventories, net 2,505 2,271
Prepaid expenses 36 99
Total current assets 3,890 3,894
Equipment, net 840 798
Patents, net 216 199
Other assets 24 53
Total assets $4,970 $4,944

LIABILITIES AND SHAREHOLDERS' EQUITY
Accounts payable $745 $537
Accrued compensation 406 392
Other accrued liabilities 367 481
Line of credit 191 --
Total current liabilities 1,709 1,410
Long-term debt -- 606
Common stock and additional paid-in capital 19,560 19,387
Accumulated (deficit) (16,299) (16,459)
Total shareholders' equity 3,261 2,928
Total liabilities and shareholders' equity $4,970 $4,944

Encision Inc.
Condensed Statements of Operations
(Amounts in thousands, except per share information)

(Unaudited) (Audited)
Three Months Ended Fiscal Years Ended
March 31, March 31, March 31, March 31,
2009 2008 2009 2008
Net sales $3,078 $3,183 $12,789 $12,066
Cost of sales 1,108 1,163 4,823 4,464
Gross profit 1,970 2,020 7,966 7,602
Operating expenses:
Sales and marketing 1,279 1,328 5,166 5,084
General and administrative 374 352 1,454 1,405
Research and development 283 279 1,139 1,268
Total operating expenses 1,936 1,959 7,759 7,757
Operating income (loss) 34 61 207 (155)
Interest and other income
(expense), net (18) (12) (47) (24)
Income (loss) before provision
for income taxes 16 49 160 (179)
Provision for income taxes -- -- -- --
Net income (loss) $16 $49 $160 $(179)
Net income (loss) per
share - basic and diluted $0.00 $0.01 $0.02 $(0.03)
Basic and diluted weighted
average number of shares 6,455 6,447 6,453 6,441

SOURCE Encision Inc.

Marcia McHaffie of Encision Inc., +1-303-444-2600, mmchaffie@encision.com